

# 4DMedical Reports 1H FY22 Results

28 February 2022

## Highlights

- Total income of \$4.8 million, up 286%, including sales revenue of \$0.2m
- Operating costs of \$17.2 million, up 47%
- Net loss after tax of \$12.5 million, down 5%
- Strong cash position with \$60.2 million as at 31 December 2021
- XV LVAS™ software rollout via initial commercial arrangement with I-MED, Australia's largest diagnostic imaging provider
- XV LVAS™ now available at I-MED sites in Berwick, Brisbane, Wagga Wagga and Albury with further locations anticipated in 2022
- Imaging complete at Johns Hopkins COPD clinical trial
- Continued progress on commercial pilots in the U.S., particularly with Veterans Health Administration
- Australian Federal Government (Medical Research Future Fund) funded XVD project to design world first dedicated lung scanner proceeding on track and on time
- Novartis U.S. pharmaceutical-led clinical program to validate therapies to treat COPD achieves 1<sup>st</sup> milestone with enrolment of clinical trial subjects
- Ms Evonne Collier appointed as independent non-executive director of 4DMedical

4DMedical Limited (ASX:4DX, "4DMedical", or the "Company"), a medical technology company focused on commercialising its FDA-cleared and TGA-approved respiratory imaging platform, is pleased to report its half-year results for the six-month period ended 31 December 2021 (1H FY22).

## Financial Performance

For the half-year ended 31 December 2021, 4DMedical reported a net loss after tax of \$12.5 million, down 5% from the previous corresponding period. Total income of \$4.8 million was up 286% or \$3.5 million from 1H FY21, derived from ongoing preclinical contracts and associated SaaS revenue of \$0.2 million and other income of \$4.6 million.

Net cash balance of the group at 31 December 2021 was \$60.2 million. Factoring in a further \$23.9m in MRFF funds yet to be received, cash reserves of the Group allow for scaling-up and execution of commercialisation opportunities as they arise.

## Commercial rollout with I-MED

During the half-year, 4DMedical made strong progress against its commercialisation strategy by securing its commercial arrangement with I-MED Radiology Network (I-MED) for the rollout of its XV Lung Ventilation Analysis Software (XV LVAS™). I-MED is Australia's largest diagnostic imaging provider, with more than 200 clinics nationwide, offering a range of diagnostic imaging services to private and public hospitals.

Through this commercial arrangement, 4DMedical's state-of-the-art respiratory technology became available to general practitioners, specialists and their patients in I-MED's clinic in Berwick, Victoria, on a pay-per-scan basis. In early 2022, 4DMedical's XV LVAS™ software was also successfully



installed at I-MED's Brisbane, Wagga Wagga and Albury sites. The Company continues to look to rapidly expand to selected locations across I-MED's nationwide network of clinics.

### **Clinical trial updates**

Clinical trials are a fundamental pillar of the 4DMedical's commercialisation strategy, and therefore, the Company was very pleased to complete imaging in the Johns Hopkins COPD trial during the period. Data from this trial will undergo analysis and the Company anticipates results will be disseminated via scientific conferences and peer reviewed journal publications in the third quarter. In addition, 4DMedical progressed discussions with hospitals to potentially partner on clinical trials specific to both the Company's XVD Scanner™ and contrast-free Ventilation-Perfusion (VQ) product.

### **Commercial pilot progress**

During the reporting period, 4DMedical continued to make progress with commercial pilots in the United States, particularly with the Veterans Health Administration (VHA) healthcare system. The VHA healthcare system represents the largest integrated healthcare system in the U.S., providing life-long care and services to eligible military veterans and their families. As announced last year, 4DMedical has won the right to paid contracts in the VHA without the need for further reimbursement.

### **Generation One XVD scanner and product pipeline**

4DMedical's vision to transform medical imaging evolved over the period by way of major advancements in the development of the Generation One prototype XVD Scanner™ at the Company's Advanced Manufacturing Facility in Port Melbourne, Victoria. This is the world's only dedicated lung scanner and integrates both advanced hardware and XV LVAS™ in one platform.

Post period end, the Company powered up this scanner, which validated its systems and functions, and subsequently passed the significant milestone of electromagnetic compatibility (EMC) testing.

In line with its FY22 outlook, 4DMedical continued its investment into research and development making excellent progress with the XVD Scanner™ and the high-value VQ product.

### **Contract with Novartis**

As previously announced, 4DMedical's U.S. pharmaceutical-led clinical program with Novartis to validate therapies to treat COPD delivered its first milestone with enrolment of clinical trial subjects. While the contract is not material in terms of revenue, the Company has invoiced Novartis for the milestone achievement, continues to build on this relationship, and looks to commercialise other opportunities in the lucrative pharmaceutical space.

### **Other corporate updates**

In December, 4DMedical appointed Ms Evonne Collier as an independent non-executive director of the Company. Ms Collier brings to 4DMedical considerable multinational experience across SaaS, sales and marketing in industries spanning MedTech, FinTech, Pharmaceutical/Health, eCommerce/Digital and FMCG.

**–ENDS–**

Authorised by the 4DMedical Board of Directors.



## Contacts

### **Corporate**

Melanie Leydin  
Company Secretary

[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### **Investor**

Simon Hinsley  
+ 61 401 809 653

[shinsley@4dmedical.com](mailto:shinsley@4dmedical.com)

### **Media**

Matthew Wright  
+ 61 451 896 420

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

### **About 4DMedical**

Based in Melbourne, Australia and Los Angeles, U.S., 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. Through its technology, 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.

For personal use only